Workflow
济民医疗(603222) - 2025 Q1 - 季度财报
ChiminChimin(SH:603222)2025-04-28 11:05

Financial Performance - The company's operating revenue for Q1 2025 was ¥181,021,832.06, a decrease of 22.49% compared to ¥233,537,436.40 in the same period last year[4] - The net profit attributable to shareholders was -¥13,636,453.43, representing a decline of 191.72% from ¥14,866,868.40 in the previous year[4] - Basic and diluted earnings per share were both -¥0.03, a decrease of 200.00% compared to ¥0.03 in the same period last year[4] - The company reported a net loss for Q1 2025, with total operating income not covering total operating costs, leading to a negative operating margin[18] - The net profit for Q1 2025 was -11,697,676.54 RMB, compared to a net profit of 18,511,661.11 RMB in Q1 2024, indicating a significant decline[19] - The total profit for Q1 2025 was -14,839,624.24 RMB, down from 19,906,503.49 RMB in the same period last year[19] - Operating profit for Q1 2025 was -14,724,154.15 RMB, compared to 21,081,215.94 RMB in Q1 2024, reflecting a substantial decrease[19] - The company reported a comprehensive income total of -9,220,897.65 RMB for Q1 2025, compared to 16,685,700.84 RMB in Q1 2024[20] Cash Flow and Assets - The net cash flow from operating activities increased by 172.61%, reaching ¥34,515,778.21, primarily due to insurance compensation received by a subsidiary[4] - Cash flow from operating activities for Q1 2025 was 34,515,778.21 RMB, an increase from 12,661,154.43 RMB in Q1 2024[24] - Cash and cash equivalents rose to $534.12 million as of March 31, 2025, compared to $313.23 million at the end of 2024, reflecting a 70.4% increase[13] - Cash and cash equivalents at the end of Q1 2025 totaled 520,565,423.47 RMB, up from 358,957,090.46 RMB at the end of Q1 2024[26] - Total current assets reached $912.87 million as of March 31, 2025, up 27.6% from $715.25 million at the end of 2024[14] Liabilities and Equity - Total liabilities increased to $1.04 billion as of March 31, 2025, compared to $846.22 million at the end of 2024, marking a 23.4% rise[15] - Total equity attributable to shareholders decreased to $1.46 billion as of March 31, 2025, from $1.48 billion at the end of 2024, a decline of 2.4%[16] - Short-term borrowings surged to $397.23 million as of March 31, 2025, compared to $180.16 million at the end of 2024, an increase of 120.5%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,687, with the top ten shareholders holding 61.67% of the shares[8] - The company plans to repurchase shares for employee stock ownership plans or equity incentives, as approved by the board[11] Investigations and Other Issues - The company is under investigation for potential criminal activities related to the former vice president's misuse of company seals[11] Research and Development - Research and development expenses increased to $11.06 million in Q1 2025, up 37.8% from $8.02 million in Q1 2024[18] Operating Costs - Total operating costs for Q1 2025 were $193.70 million, down 10.7% from $217.02 million in Q1 2024[18]